I agree with you... if BIEL products start to show sales acceleration, they will without a doubt get noticed by big pharma (if not already for their patent).
And because they do not have the capacity (yet) to distribute millions of patches per month, they will either need to license the technology to others, go into joint ventures, or put themselves on the block for sale when that time comes.
Nice to dream, eh?
News 
Market Data 
Discover 
AI
